Advertisement

Effects of Polyunsaturated Fatty Acid Treatment on Postdischarge Outcomes After Acute Myocardial Infarction

Published:November 17, 2015DOI:https://doi.org/10.1016/j.amjcard.2015.10.050
      Clinical trials studying the efficacy of n-3 polyunsaturated fatty acids (PUFA) in reducing adverse events after acute myocardial infarction (AMI) have yielded conflicting results, and data regarding the influence of n-3 PUFA treatment after AMI in routine clinical practice are scarce. We conducted a retrospective observational cohort study including patients from 5 Italian Local Health Units who were discharged from the hospital with a primary diagnosis of AMI from January 1, 2010, to December 31, 2011. Using unique patient identifiers, patients were linked across governmental hospital discharge, medication prescription, and mortality databases and followed for 12-months post-index discharge. Patient characteristics and risk of all-cause mortality and repeat AMI were compared by n-3 PUFA prescription after discharge (for outcome analyses, defined as ≥2 prescriptions) at a presumed dose of 1 g/day. Overall, 11,269 patients met inclusion criteria, of which 2,425 patients (21.5%) were prescribed n-3 PUFA during follow-up. Patients treated with n-3 PUFA tended to be younger, men, and carry a diagnosis of diabetes and were more likely to be receiving guideline-recommended post-AMI medical therapy, including β blockers, angiotensin-converting enzyme inhibitors/angiotensin II receptor blockers, statins, and antiplatelet therapy (all p <0.001). After adjusting for patient characteristics and concurrent therapies, n-3 PUFA treatment was associated with reduced all-cause mortality (hazard ratio 0.76, 95% CI 0.59 to 0.97) and recurrent AMI (hazard ratio 0.65, 95% CI 0.49 to 0.87) through 12-month follow-up. In conclusion, in this large, contemporary, observational study of “real-world” Italian patients hospitalized for AMI, the use of n-3 PUFA was independently associated with a robust reduction in all-cause mortality and recurrent AMI. These data support further randomized controlled trials with n-3 PUFA therapy in the post-AMI setting.
      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribe:

      Subscribe to American Journal of Cardiology
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

      1. Dietary supplementation with n-3 polyunsaturated fatty acids and vitamin E after myocardial infarction: results of the GISSI-Prevenzione trial. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto miocardico.
        Lancet. 1999; 354: 447-455
        • Marchioli R.
        • Barzi F.
        • Bomba E.
        • Chieffo C.
        • Di Gregorio D.
        • Di Mascio R.
        • Franzosi M.G.
        • Geraci E.
        • Levantesi G.
        • Maggioni A.P.
        • Mantini L.
        • Marfisi R.M.
        • Mastrogiuseppe G.
        • Mininni N.
        • Nicolosi G.L.
        • Santini M.
        • Schweiger C.
        • Tavazzi L.
        • Tognoni G.
        • Tucci C.
        • Valagussa F.
        • GISSI-Prevenzione Investigators
        Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico (GISSI)-Prevenzione.
        Circulation. 2002; 105: 1897-1903
        • Kromhout D.
        • Giltay E.J.
        • Geleijnse J.M.
        Alpha Omega trial group. n-3 fatty acids and cardiovascular events after myocardial infarction.
        N Engl J Med. 2010; 363: 2015-2026
        • Rauch B.
        • Schiele R.
        • Schneider S.
        • Diller F.
        • Victor N.
        • Gohlke H.
        • Gottwik M.
        • Steinbeck G.
        • Del Castillo U.
        • Sack R.
        • Worth H.
        • Katus H.
        • Spitzer W.
        • Sabin G.
        • Senges J.
        • OMEGA Study Group
        OMEGA, a randomized, placebo-controlled trial to test the effect of highly purified omega-3 fatty acids on top of modern guideline-adjusted therapy after myocardial infarction.
        Circulation. 2010; 122: 2152-2159
        • Galan P.
        • Kesse-Guyot E.
        • Czernichow S.
        • Briancon S.
        • Blacher J.
        • Hercberg S.
        • SU.FOL.OM3 Collaborative Group
        Effects of B vitamins and omega 3 fatty acids on cardiovascular diseases: a randomised placebo controlled trial.
        BMJ. 2010; 341: c6273
        • McNamara R.L.
        • Chung S.C.
        • Jernberg T.
        • Holmes D.
        • Roe M.
        • Timmis A.
        • James S.
        • Deanfield J.
        • Fonarow G.C.
        • Peterson E.D.
        • Jeppsson A.
        • Hemingway H.
        International comparisons of the management of patients with non-ST segment elevation acute myocardial infarction in the United Kingdom, Sweden, and the United States: the MINAP/NICOR, SWEDEHEART/RIKS-HIA, and ACTION Registry-GWTG/NCDR registries.
        Int J Cardiol. 2014; 175: 240-247
        • Chan M.Y.
        • Mahaffey K.W.
        • Sun L.J.
        • Pieper K.S.
        • White H.D.
        • Aylward P.E.
        • Ferguson J.J.
        • Califf R.M.
        • Roe M.T.
        Prevalence, predictors, and impact of conservative medical management for patients with non-ST-segment elevation acute coronary syndromes who have angiographically documented significant coronary disease.
        JACC Cardiovasc Interv. 2008; 1: 369-378
        • Roe M.T.
        • White J.A.
        • Kaul P.
        • Tricoci P.
        • Lokhnygina Y.
        • Miller C.D.
        • van't Hof A.W.
        • Montalescot G.
        • James S.K.
        • Saucedo J.
        • Ohman E.M.
        • Pollack Jr., C.V.
        • Hochman J.S.
        • Armstrong P.W.
        • Giugliano R.P.
        • Harrington R.A.
        • Van de Werf F.
        • Califf R.M.
        • Newby L.K.
        Regional patterns of use of a medical management strategy for patients with non-ST-segment elevation acute coronary syndromes: insights from the EARLY ACS trial.
        Circ Cardiovasc Qual Outcomes. 2012; 5: 205-213
        • Rasmussen J.N.
        • Chong A.
        • Alter D.A.
        Relationship between adherence to evidence-based pharmacotherapy and long-term mortality after acute myocardial infarction.
        JAMA. 2007; 297: 177-186
        • Ho P.M.
        • Spertus J.A.
        • Masoudi F.A.
        • Reid K.J.
        • Peterson E.D.
        • Magid D.J.
        • Krumholz H.M.
        • Rumsfeld J.S.
        Impact of medication therapy discontinuation on mortality after myocardial infarction.
        Arch Intern Med. 2006; 166: 1842-1847
        • Heydari B.
        • Abbasi S.A.
        • Shah R.
        • Abdullah S.
        • Feng J.
        • Harris W.
        • McConnell J.
        • Appelbaum E.
        • Hoffmann U.
        • Steigner M.
        • Blankstein R.
        • Antman E.A.
        • Jerosch-Herold M.
        • Kwong R.Y.
        Effect of purified omega-3 fatty acids on reducing left ventricular remodeling after acute myocardial infarction (OMEGA-REMODEL study): a double-blind randomized clinical trial.
        J Cardiovasc Magn Reson. 2015; 17: 7
        • Rizos E.C.
        • Ntzani E.E.
        • Bika E.
        • Kostapanos M.S.
        • Elisaf M.S.
        Association between omega-3 fatty acid supplementation and risk of major cardiovascular disease events: a systematic review and meta-analysis.
        JAMA. 2012; 308: 1024-1033
        • Delgado-Lista J.
        • Perez-Martinez P.
        • Lopez-Miranda J.
        • Perez-Jimenez F.
        Long chain omega-3 fatty acids and cardiovascular disease: a systematic review.
        Br J Nutr. 2012; 107: S201-S213
        • Dharmarajan K.
        • Hsieh A.F.
        • Kulkarni V.T.
        • Lin Z.
        • Ross J.S.
        • Horwitz L.I.
        • Kim N.
        • Suter L.G.
        • Lin H.
        • Normand S.L.
        • Krumholz H.M.
        Trajectories of risk after hospitalization for heart failure, acute myocardial infarction, or pneumonia: retrospective cohort study.
        BMJ. 2015; 350: h411
        • Lavie C.J.
        • Milani R.V.
        • Mehra M.R.
        • Ventura H.O.
        Omega-3 polyunsaturated fatty acids and cardiovascular diseases.
        J Am Coll Cardiol. 2009; 54: 585-594
        • Masoudi F.A.
        • Ponirakis A.
        • Yeh R.W.
        • Maddox T.M.
        • Beachy J.
        • Casale P.N.
        • Curtis J.P.
        • De Lemos J.
        • Fonarow G.
        • Heidenreich P.
        • Koutras C.
        • Kremers M.
        • Messenger J.
        • Moussa I.
        • Oetgen W.J.
        • Roe M.T.
        • Rosenfield K.
        • Shields Jr., T.P.
        • Spertus J.A.
        • Wei J.
        • White C.
        • Young C.H.
        • Rumsfeld J.S.
        Cardiovascular care facts: a report from the national cardiovascular data registry: 2011.
        J Am Coll Cardiol. 2013; 62: 1931-1947
        • Amsterdam E.A.
        • Wenger N.K.
        • Brindis R.G.
        • Casey Jr., D.E.
        • Ganiats T.G.
        • Holmes Jr., D.R.
        • Jaffe A.S.
        • Jneid H.
        • Kelly R.F.
        • Kontos M.C.
        • Levine G.N.
        • Liebson P.R.
        • Mukherjee D.
        • Peterson E.D.
        • Sabatine M.S.
        • Smalling R.W.
        • Zieman S.J.
        2014 AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: a report of the American college of Cardiology/American heart association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2014; 64: e139-e228
        • Kushner F.G.
        • Hand M.
        • Smith Jr., S.C.
        • King 3rd, S.B.
        • Anderson J.L.
        • Antman E.M.
        • Bailey S.R.
        • Bates E.R.
        • Blankenship J.C.
        • Casey Jr., D.E.
        • Green L.A.
        • Hochman J.S.
        • Jacobs A.K.
        • Krumholz H.M.
        • Morrison D.A.
        • Ornato J.P.
        • Pearle D.L.
        • Peterson E.D.
        • Sloan M.A.
        • Whitlow P.L.
        • Williams D.O.
        2009 focused updates: ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update) a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.
        J Am Coll Cardiol. 2009; 54: 2205-2241
        • Macchia A.
        • Romero M.
        • D'Ettorre A.
        • Tognoni G.
        • Mariani J.
        Exploratory analysis on the use of statins with or without n-3 PUFA and major events in patients discharged for acute myocardial infarction: an observational retrospective study.
        PloS One. 2013; 8: e62772
        • Nishio R.
        • Shinke T.
        • Otake H.
        • Nakagawa M.
        • Nagoshi R.
        • Inoue T.
        • Kozuki A.
        • Hariki H.
        • Osue T.
        • Taniguchi Y.
        • Iwasaki M.
        • Hiranuma N.
        • Konishi A.
        • Kinutani H.
        • Shite J.
        • Hirata K.
        Stabilizing effect of combined eicosapentaenoic acid and statin therapy on coronary thin-cap fibroatheroma.
        Atherosclerosis. 2014; 234: 114-119
        • Eapen Z.J.
        • Lauer M.S.
        • Temple R.J.
        The imperative of overcoming barriers to the conduct of large, simple trials.
        JAMA. 2014; 311: 1397-1398
        • Eapen Z.J.
        • Vavalle J.P.
        • Granger C.B.
        • Harrington R.A.
        • Peterson E.D.
        • Califf R.M.
        Rescuing clinical trials in the United States and beyond: a call for action.
        Am Heart J. 2013; 165: 837-847
        • Frobert O.
        • Lagerqvist B.
        • Olivecrona G.K.
        • Omerovic E.
        • Gudnason T.
        • Maeng M.
        • Aasa M.
        • Angeras O.
        • Calais F.
        • Danielewicz M.
        • Erlinge D.
        • Hellsten L.
        • Jensen U.
        • Johansson A.C.
        • Karegren A.
        • Nilsson J.
        • Robertson L.
        • Sandhall L.
        • Sjogren I.
        • Ostlund O.
        • Harnek J.
        • James S.K.
        Thrombus aspiration during ST-segment elevation myocardial infarction.
        N Engl J Med. 2013; 369: 1587-1597
        • Rao S.V.
        • Hess C.N.
        • Barham B.
        • Aberle L.H.
        • Anstrom K.J.
        • Patel T.B.
        • Jorgensen J.P.
        • Mazzaferri Jr., E.L.
        • Jolly S.S.
        • Jacobs A.
        • Newby L.K.
        • Gibson C.M.
        • Kong D.F.
        • Mehran R.
        • Waksman R.
        • Gilchrist I.C.
        • McCourt B.J.
        • Messenger J.C.
        • Peterson E.D.
        • Harrington R.A.
        • Krucoff M.W.
        A registry-based randomized trial comparing radial and femoral approaches in women undergoing percutaneous coronary intervention: the SAFE-PCI for Women (Study of Access Site for Enhancement of PCI for Women) trial.
        JACC Cardiovasc Interv. 2014; 7: 857-867